MedPage Today on MSN

Sjogren's Disease and Cardiovascular Risks

Heart disease may accompany extraglandular involvement ...
Healio

Ianalumab may help patients with CLL stop daily, indefinite treatment with ibrutinib

Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, ...
pharmaphorum

J&J gets EU approval for Imaavy in gMG

Johnson & Johnson's Imaavy has become the first FcRn blocker to be approved in the EU as a treatment for both adolescent and ...
Zacks.com on MSN

JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis

Johnson & Johnson JNJ announced that the European Commission has approved Imaavy (nipocalimab) as an add-on therapy for the ...
The Manila Times

Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...